PUBLICATIONS


5) Anderegg N, Johnson LF, Zaniewski E, Althoff KN, Balestre E, Law M, Nash D, Shepherd BE, Yiannoutsos CT, Egger M; IeDEA, MeSH consortia. All-cause mortality in HIV-positive adults starting combination antiretroviral therapy: correcting for loss to follow-up. AIDS. 2017 Apr;31 Suppl 1:S31-S40. PMCID: PMC5540664


8) Rebeiro PF, Abraham AG, Horberg MA, Althoff KN, Yehia BR, Buchacz K, Lau BM, Sterling TR, Gange SJ. Sex, Race, and HIV Risk Disparities in Discontinuity of HIV Care After Antiretroviral Therapy Initiation in the United States and Canada. AIDS Patient Care STDS. 2017 Mar;31(3):129-144 Epub 2017 Feb 27. PMCID: PMC5359655


12) Althoff KN. **The Shifting Paradigm of Care for Adults Living With HIV: Smoking Cessation for Longer Life.** J Infect Dis. 2016 Dec 1;214(11):1618-1620. PMCID: PMC5144730


25) Poteat T, Hanna DB, Althoff KN. Feasibility and acceptability of developing a multi-site clinical cohort of transgender people with HIV infection. AIDS Res Hum Retroviruses. 2015 Sep;31(9):870-2. PMID: PMC4808270


50) Kitahata MM. When to start antiretroviral therapy. Top HIV Med. 2010 Aug-Sep;18(3):121-6. PMC20921578


PRESENTATIONS & REPORTS

2017

**2017 Conference on Retroviruses and Opportunistic Infections (CROI), Seattle**

2) Althoff KN, Horberg MA, Eron, J, Gange SJ, Crane HM, Justice AC, Kitahata MM, Margolick JB, Eyawo O, Moore RD. **The large gap between statin eligibility and prescription among HIV+ in North America.** (Poster)

3) Desir F, Rebeiro PF, Moore RD, Crane HM, Gabler K, Margolick JB, Bosch R, Horberg MA, Silverberg MJ, Althoff KN. **Retention, ART use, and viral suppression among young adults newly linked to HIV care.** (Poster)


**2017 International Workshop on HIV Observational Databases (IWHOD), Lisbon, Portugal**


**2016**

**2016 WHO Report**


**2016 Inter-CFAR Collaboration on HIV Research in Women Symposium, Birmingham**

9) Desir FA, Rebeiro PF, Moore RD, Crane HM, Gabler K, Margolick JB, Bosch R, Horberg MA, Silverberg MJ, and Althoff KN. **Retention, ART use, and viral suppression among women linked to HIV care in the United States.** (Oral)

**2016 International AIDS Conference, Durban, South Africa**


**2016 International Workshop on HIV Observational Databases (IWHOD), Budapest, Hungary**

11) Rohner E, **CD4 cell trajectories in HIV-positive adults developing Kaposi Sarcoma after starting cART: a multiregional comparison based on nested case control studies.** (Poster)

12) Olga Tymejczyk, Constantin Yiannoutsos, Kara Wools-Kaloustian, Amit Achhra, Keri Althoff, Brenda Crabtree-Ramirez, Kinh Van Nguyen, Elizabeth Zaniewski, and Denis Nash for the IeDEA


14) George Rutherford, Aaron Kipp, Mary Lou Lindegren, Bryan E. Shepherd, C. William Wester, Kara Woolf-Kalousian, Constantin T. Yiannoutsos for the International epidemiological Databases to Evaluate AIDS (IeDEA) Consortium Comparison of 48- and 96-week outcomes in adults initiating tenofovir + lamivudine/emtricitabine + efavirenz and those initiating two other nucleoside reverse transcriptase inhibitors + efavirenz using propensity-score matched IeDEA observational cohort data and data from randomised controlled trials. (Oral)

**2016 Conference on Retroviruses and Opportunistic Infections (CROI), Boston**


**2016 American Society of Clinical Oncology (ASCO), Chicago**

22) Rohner E, Büttikofer L, Maskew M, Fink V, Grinsztejn B, Achenbach C, Goedert J, Bohlius J. NHL risk in HIV+ Adults on Antiretroviral Therapy in Four Continents (Poster)
2015

**2015 International AIDS Society (IAS), Vancouver**

23) Calkins K, Eron JJ, Abraham AG, Buchacz K, Horberg MA, Tate J, Napravnik S, Moore RD, Bosch RJ, Lau B. **CD4 reconstitution is related to CD4 at effective antiretroviral treatment initiation** (Poster)

**2015 Conference on Retroviruses and Opportunistic Infections (CROI), Seattle**


26) IeDEA and COHERE collaboration. **Immunodeficiency at the Start of ART: A Global View** (Themed Discussion)


29) Ingle SM, Miro JM, Furrer H, Justice AC, Saag MS, Manzardo C, Esteve A, Cain LE, Sterne JAC, May MT on behalf of COHERE in EuroCoord, CNICS and NA-ACCORD. **Impact of ART on Mortality in Cryptococcal Meningitis Patients: High-Income Settings** (Themed Discussion)

30) Rebeiro PF, Yehia BR, Gebo KA, Lau B, Mayer KH, Horberg MA, Kitahata MM, Gill MJ. **Continuous Retention Predicts Viral Suppression Across the US and Canada** (Poster)


32) Cesar CT, Giganti MJ, Shepherd BE, Moore RD, Althoff KN, Napravnik S, Mayor AM, McGowan C, Cahn PE. **Outcomes of first ART in Latino populations in North America and Latin America** (Poster)

**2015 International Workshop on HIV Observational Databases (IWHOD), Catania, Sicily**


35) Pettit AC, Mendes A, Jenkins CA, Napravnik S, Freeman AM, Shepherd BE, Dowdy D, Rachlis A, Moore RD, and Sterling TR. **Highly Active Antiretroviral Therapy Initiation and Incident TB in the US and Canada** (Oral)

2015 National Transgender Health Summit, Oakland, CA

37) Poteat T, Hanna D. The feasibility and acceptability of developing a multi-site clinical cohort of transgender people with HIV infection (Oral)

2015 Society for Research on Nicotine and Tobacco (SRNT), Philadelphia.


2015 Pepper Center Annual Meeting, Arlington


2014

2014 International Workshop on HIV Observational Databases (IWHOD), Sitges, Spain


2014 Conference on Retroviruses and Opportunistic Infections (CROI), Boston


(NA-ACCORD) of the IeDEA. **Body Mass Index and CD4+ T-cell Recovery at 12 Months among Adults Initiating ART in the United States and Canada.** (Poster)

46) Pettit AC, Mendes A, Jenkins CA, Napravnik S, Freeman AM, Shepherd BE, Dowdy DR, Rachlis A, Moore RD and Sterling TR, for the NA-ACCORD investigators and IeDEA. **Antiretroviral Therapy Initiation and Tuberculosis (TB) Risk in the United States (US) and Canada.** (Poster)

47) Yehia BR, Rebeiro PF, Althoff KN, Gange SJ, Samji H, Horberg MA, Napravnik S and Gebo KA for the NA-ACCORD and IeDEA. **Age Impacts the Association of Retention in Care and Viral Suppression.** (Poster)

### 2013

#### 2013 IAS, Malaysia


#### 2013 International Workshop on HIV Observational Databases (IWHOD), Croatia


53) Janet Tate, Justice AC. **Does change in VACS Index predict mortality better than viral suppression and CD4 after one year of ART?** (Oral)
2013 Conference on Retroviruses and Opportunistic Infections (CROI), Atlanta


2012

2012 XIX International AIDS Conference


2012 Society for Epidemioviral Research

65) Hanna DB, Stuart EA and Gange SJ for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA. Use of Propensity Score Matching to Assess the Effect of a State Policy on Treatment Outcomes in U.S. HIV-infected Persons. (Poster)


2012 Eurogin


2012 International Workshop on HIV Observational Databases (IWHOD), Athens


2012 Conference on Retroviruses and Opportunistic Infections (CROI), Seattle

Design (NA-ACCORD) of IeDEA. Incidence and Risk Factors for Oral Cancer Among HIV-Infected Individuals. (Oral)


2012 Report to the Institute of Medicine


2011

2011 Conference on Retroviruses and Opportunistic Infections (CROI), Boston

74) Justice AC, Modur SP, Tate J, Althoff KN, Gange SJ, Jacobson LP, Gebo K, Kitahata MM, Horberg MA, Napravnik S for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA. A Prognostic Index for those Aging with HIV: Extension of the VACS Index to those on Combination Anti-Retroviral Therapy (cART). (Poster)


2011 International Workshop on HIV Observational Databases (IWHOD), Prague

76) Althoff KN, Gange SJ, Klein MB, Brooks JT, Hogg RS, Bosch RJ, Horberg MA, Saag MS and Moore RD for the NA-ACCORD. Characteristics of late presenters and timing of antiretroviral therapy initiation. (Oral)


2011 XVIII International AIDS Conference

2011 12th International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies


2010

2010 International Workshop on HIV Observational Databases (IWHOD), Sitges, Spain
82) Gange SJ. Methods for Evaluating When to Start Antiretroviral Therapy. Invited plenary session speaker, 14th International Workshop on HIV Observational Databases, Sitges, Spain.


2010 Conference on Retroviruses and Opportunistic Infections (CROI), San Francisco


2010 1st International Workshop on HIV & Aging


2010 Reports


93) DHHS Panel on Antiretroviral Treatment Guidelines Annual Meeting at CROI, Montreal: Kitahata MM, Gange SG, Moore RD. Summary of 351-500 (ICAAC/IDSA 2008) and >500 (CROI 2009) presentations. (Oral presentation via special invitation from panel)

2009

2009 Conference on Retroviruses and Opportunistic Infections (CROI), Montreal

94) Kitahata MM, Gange SG, Moore RD and North American AIDS Cohort Collaboration Research and Design (NA-ACCORD) of the IeDEA. Initiating Rather than Deferring HAART at a CD4 count >500 cells/mm³ is Associated with Improved Survival. (Oral)

2009 13th International Workshop on HIV Observational Databases (IWHOD), Lisbon


96) Althoff KN, Gange SJ, Gebo KA and North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of the IeDEA. Title: Older age is inversely associated with immune recovery after HAART initiation in North America. (Poster)
2008

2008 Conference on Retroviruses and Opportunistic Infections (CROI), Boston


98) Sterling TR and North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of the IeDEA. Tuberculosis after HAART Initiation in the United States and Canada. (Poster)

2008 12th International Workshop on HIV Observational Databases (IWHOD), Spain


2008 IAS, Mexico


101) Sterling TR and North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of the IeDEA. Risk Factors for Tuberculosis Within 3 Months of HAART Initiation. (Oral)

2008 XVII International Resistance Workshop, Spain


2008 Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), Washington

103) Kitahata MM and North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of the IeDEA. Initiating Rather than Deferring HAART at a CD4 count Between 351-500 cells/mm3 is Associated with Improved Survival. (Oral)

2008 NIAID/DAIDS Meeting, Bethesda

104) Initiating Rather than Deferring HAART at a CD4+ Count Between 351-500 Cells/mm³ is Associated with Improved Survival. (Special invitation to present a summary of the ICAAC/IDSA presentation)